Hypertension Treatment in Nigeria 2.0

Study acronym: HTN 2
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Trial sites expanded: 0 → 49 locations
    • Start date changed from estimate of Feb 1, 2026 to Feb 2, 2026
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 10 of 13 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary healthcare centers (PHCs) in the Federal Capital Territory, Nigeria. This program demonstrated significant improvements in hypertension treatment and control. HTN 2.0 will expand implementation of the HEARTS bundle to 5 new states in 5 geopolitical zones in Nigeria (Abia, Delta, Gombe, Jigawa, and Oyo) while also evaluating sustainment of hypertension control in the Federal Capital Territory.
Trial Details
NCT Number NCT07351162
Lead Sponsor Washington University School of Medicine
Collaborators: University of Abuja Teaching Hospital, University of Abuja, National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)		 Hypertension (HTN)
Related terms Hypertension
Enrollment 10,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov